Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JPS6148511B2 - - Google Patents
[go: Go Back, main page]

JPS6148511B2 - - Google Patents

Info

Publication number
JPS6148511B2
JPS6148511B2 JP9845278A JP9845278A JPS6148511B2 JP S6148511 B2 JPS6148511 B2 JP S6148511B2 JP 9845278 A JP9845278 A JP 9845278A JP 9845278 A JP9845278 A JP 9845278A JP S6148511 B2 JPS6148511 B2 JP S6148511B2
Authority
JP
Japan
Prior art keywords
methyl
butenyloxy
bis
methanol
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP9845278A
Other languages
Japanese (ja)
Other versions
JPS5527112A (en
Inventor
Kazuaki Kyogoku
Katsuo Hatayama
Sadakazu Yokomori
Yutaka Kawashima
Jiro Sawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP9845278A priority Critical patent/JPS5527112A/en
Publication of JPS5527112A publication Critical patent/JPS5527112A/en
Publication of JPS6148511B2 publication Critical patent/JPS6148511B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

本発明はフラボン誘導体に関し、抗消化性潰瘍
作用を有する新規な化合物を提供するものであ
る。本発明の目的化合物は、 一般式 (式中、X1とX2のうち1個は3−メチル−2−ブ
テニロキシ基を示し、その余は水素原子を示す。
〓〓〓は単一結合または二重結合を示す。)で表
わされるフラボン誘導体である。 本発明の化合物は例えば次のようにして製造す
ることができる。 即ち、 2′−ハイドロキシ−4・4′−ビス(3−メチル
−2−ブテニロキシ)カルコンまたは2′−ハイド
ロキシ−2・4′−ビス(3−メチル−2−ブテニ
ロキシ)カルコンを出発原料とする。 1モルの出発原料に約1モルの苛性アルカリ
(水酸化カリウム、水酸化ナトリウムなど)と5
モルの30%過酸化水素を加え、室温で4〜5時間
撹拌しつつ反応させてフラボノール誘導体とする
かまたは1モルの出発原料に約0.5モルの苛性ア
ルカリ(水酸化カリウム、水酸化ナトリウムな
ど)と5モルの30%過酸化水素を加え、室温で4
〜5時間撹拌しつつ反応させてフラバノノール誘
導体とする。 本発明の化合物は抗消化性潰瘍作用がすぐれて
いるばかりでなく毒性も低く、医薬として有用で
ある。 次に本発明の化合物の抗消化性潰瘍作用を示す
試験例と本発明の化合物の製造例を示す実施例を
挙げて本発明を具体的に説明する。 試験例 ラツト(各群10匹)を用いてShayの幽門結紮
法(腹腔内投与量50mg/Kg)により本発明の化合
物の潰瘍抑制率を求めた。 その結果を表に示す。 なお、マウス(各群10匹)に本発明の化合物1
g/Kgを経口投与したが、死亡例は認められなか
つた。
The present invention relates to flavone derivatives and provides novel compounds having anti-peptic ulcer activity. The object compound of the present invention has the general formula (In the formula, one of X 1 and X 2 represents a 3-methyl-2-butenyloxy group, and the rest represent hydrogen atoms.
〓〓〓 indicates a single bond or a double bond. ) is a flavone derivative represented by The compound of the present invention can be produced, for example, as follows. That is, 2'-hydroxy-4,4'-bis(3-methyl-2-butenyloxy)chalcone or 2'-hydroxy-2,4'-bis(3-methyl-2-butenyloxy)chalcone is used as a starting material. . About 1 mol of caustic alkali (potassium hydroxide, sodium hydroxide, etc.) and 5 mol of starting material
Add 30% mole of hydrogen peroxide and react with stirring at room temperature for 4 to 5 hours to obtain a flavonol derivative, or add about 0.5 mole of caustic alkali (potassium hydroxide, sodium hydroxide, etc.) to 1 mole of starting material. and 5 moles of 30% hydrogen peroxide, and 4
The reaction is carried out with stirring for ~5 hours to obtain a flavanonol derivative. The compounds of the present invention not only have excellent anti-peptic ulcer effects but also have low toxicity, making them useful as medicines. Next, the present invention will be specifically explained with reference to test examples showing the anti-peptic ulcer activity of the compounds of the present invention and examples showing production examples of the compounds of the present invention. Test Example The ulcer inhibition rate of the compound of the present invention was determined using Shay's pyloric ligation method (intraperitoneal dose: 50 mg/Kg) using rats (10 rats in each group). The results are shown in the table. In addition, the compound 1 of the present invention was administered to mice (10 mice in each group).
g/Kg was administered orally, but no deaths were observed.

【表】 実施例 1 2′−ハイドロキシ−4・4′−ビス(3−メチル
−2−ブテニロキシ)カルコン(mp87〜89℃)
3gをメタノール150mlに容解し、これに水酸化
カリウム430mgを加え、更に冷却下に30%過酸化
水素4mlを加えて、室温で4時間撹拌して反応さ
せた。反応終了後メタノールをほとんど留去し、
酢酸エチルで抽出し、芒硝で乾燥した。酢酸エチ
ルを留去後シリカゲルカラムクロマトグラフイー
(展開溶媒:クロロホルム)に付し、アセトンで
再結晶し0.5gの4′・7−ビス(3−メチル−2
−ブテニロキシ)フラボノールを得た。 mp 167〜168℃ 実施例 2 2′−ハイドロキシ−2・4′−ビス(3−メチル
−2−ブテニロキシ)カルコン(mp74〜75℃)
1.5gをメタノール100mlに溶解し、これに水酸化
カリウム215mgを加え、更に冷却下30%過酸化水
素2mlを加えて、室温で4時間撹拌して反応させ
た。 反応終了後メタノールをほとんど留去し、エー
テルで抽出し、芒硝で乾燥させた。エーテル留去
後シリカゲルカラムクロマトグラフイー(展開溶
媒:n−ヘキサン:アセトン=9:1)に付し、
メタノールで再結晶して0.3gの2′・7−ビス
(3−メチル−2−ブテニロキシ)フラボノール
を得た。 mp 142〜144℃ 実施例 3 2′−ハイドロキシ−4・4′−ビス(3−メチル
−2−ブテニロキシ)カルコン(mp87〜89℃)
400mgをメタノール20mlに溶解し、これに水酸化
カリウム28mgを加え、更に冷却下に30%過酸化水
素0.5mlを加えて、室温で4時間撹拌して反応さ
せた。 反応終了後メタノールを留去、エーテルで抽出
し、芒硝で乾燥した。エーテル留去後シリカゲル
カラムクロマトグラフイー(展開溶媒:n−ヘキ
サン:アセトン=3:1)に付し、n−ヘキサン
で再結晶し、200mgの4′・7−ビス(3−メチル
−2−ブテニロキシ)フラバノノールを得た。 mp 109〜110℃ 実施例 4 2′−ハイドロキシ−2・4′−ビス(3−メチル
−2−ブテニロキシ)カルコン(mp74〜75℃)
400mgをメタノール20mlに溶解、これに水酸化カ
リウム28mgを加え、更に冷却下に30%過酸化水素
0.5mlを加えて、室温で5時間撹拌して反応させ
た。反応終了後メタノールを留去し、エーテルで
抽出し、芒硝で乾燥した。エーテル留去後、シリ
カゲルカラムクロマトグラフイー(展開溶媒 n
−ヘキサン:アセトン=3:1)に付し、n−ヘ
キサンで再結晶し、190mgの2′・7−ビス(3−
メチル−2−ブテニロキシ)フラバノノールを得
た。mp 104〜106℃
[Table] Example 1 2'-Hydroxy-4,4'-bis(3-methyl-2-butenyloxy)chalcone (mp87-89℃)
3 g was dissolved in 150 ml of methanol, 430 mg of potassium hydroxide was added thereto, and further, 4 ml of 30% hydrogen peroxide was added while cooling, and the mixture was stirred at room temperature for 4 hours to react. After the reaction is complete, most of the methanol is distilled off.
It was extracted with ethyl acetate and dried with Glauber's salt. After distilling off ethyl acetate, it was subjected to silica gel column chromatography (developing solvent: chloroform) and recrystallized from acetone to obtain 0.5 g of 4',7-bis(3-methyl-2
-butenyloxy)flavonol was obtained. mp 167-168℃ Example 2 2'-Hydroxy-2,4'-bis(3-methyl-2-butenyloxy)chalcone (mp74-75℃)
1.5 g was dissolved in 100 ml of methanol, 215 mg of potassium hydroxide was added thereto, and further, 2 ml of 30% hydrogen peroxide was added under cooling, and the mixture was stirred at room temperature for 4 hours to react. After the reaction was completed, most of the methanol was distilled off, extracted with ether, and dried over Glauber's salt. After distilling off the ether, it was subjected to silica gel column chromatography (developing solvent: n-hexane:acetone = 9:1),
Recrystallization from methanol yielded 0.3 g of 2'.7-bis(3-methyl-2-butenyloxy)flavonol. mp 142-144℃ Example 3 2'-Hydroxy-4,4'-bis(3-methyl-2-butenyloxy)chalcone (mp87-89℃)
400 mg was dissolved in 20 ml of methanol, 28 mg of potassium hydroxide was added thereto, and further, 0.5 ml of 30% hydrogen peroxide was added under cooling, and the mixture was stirred at room temperature for 4 hours to react. After the reaction was completed, methanol was distilled off, extracted with ether, and dried over Glauber's salt. After distilling off the ether, it was subjected to silica gel column chromatography (developing solvent: n-hexane:acetone = 3:1), recrystallized from n-hexane, and 200 mg of 4',7-bis(3-methyl-2- Butenyloxy) flavanonol was obtained. mp 109-110℃ Example 4 2'-Hydroxy-2,4'-bis(3-methyl-2-butenyloxy)chalcone (mp74-75℃)
Dissolve 400mg in 20ml of methanol, add 28mg of potassium hydroxide, and add 30% hydrogen peroxide while cooling.
0.5 ml was added and stirred at room temperature for 5 hours to react. After the reaction was completed, methanol was distilled off, extracted with ether, and dried over Glauber's salt. After distilling off the ether, silica gel column chromatography (developing solvent n
-hexane:acetone=3:1), recrystallized from n-hexane, and 190 mg of 2',7-bis(3-
Methyl-2-butenyloxy) flavanonol was obtained. mp 104~106℃

Claims (1)

【特許請求の範囲】 1 一般式 (式中、X1とX2のうち1個は3−メチル−2−ブ
テニロキシ基を示し、その余は水素原子を示す。
〓〓は単一結合または二重結合を示す。)で表わ
されるフラボン誘導体。
[Claims] 1. General formula (In the formula, one of X 1 and X 2 represents a 3-methyl-2-butenyloxy group, and the rest represent hydrogen atoms.
〓〓 indicates a single bond or a double bond. ) flavone derivatives.
JP9845278A 1978-08-12 1978-08-12 Flavone derivative Granted JPS5527112A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9845278A JPS5527112A (en) 1978-08-12 1978-08-12 Flavone derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9845278A JPS5527112A (en) 1978-08-12 1978-08-12 Flavone derivative

Publications (2)

Publication Number Publication Date
JPS5527112A JPS5527112A (en) 1980-02-27
JPS6148511B2 true JPS6148511B2 (en) 1986-10-24

Family

ID=14220101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9845278A Granted JPS5527112A (en) 1978-08-12 1978-08-12 Flavone derivative

Country Status (1)

Country Link
JP (1) JPS5527112A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399584A (en) * 1992-05-05 1995-03-21 The Procter & Gamble Company Use of flavone derivatives for gastroprotection
DE102011120361B4 (en) 2011-12-07 2022-09-29 ThyssenKrupp Carbon Components GmbH Wheel rims with a fiber composite rim well and method of manufacture

Also Published As

Publication number Publication date
JPS5527112A (en) 1980-02-27

Similar Documents

Publication Publication Date Title
JP2509683B2 (en) Specific 3-substituted 2-alkylbenzofuran derivatives
GB2054566A (en) 1-aryl-4-arylsulphonyl-3-aminopropoxy-1h-pyrazoles medicaments containing them and processes for their preparation
EP0199393A1 (en) Indene and naphthalene derivatives
JPS6148511B2 (en)
JPS628421B2 (en)
JPS6115058B2 (en)
JPS598249B2 (en) Synthesis method of chalcones
US3322778A (en) Novel ether derivatives of benzmorphans
US2858317A (en) Process for preparing isonicotinic acid diethylamide
JPS6377868A (en) Alpha-(omega-hydroxyalkyl)furfuryl alcohol and production thereof
JPH0378384B2 (en)
JPS59144753A (en) Fluoroprostaglandin and manufacture
JPS5912094B2 (en) Synthesis method of chalcone bodies
KR100376280B1 (en) Method for preparing cinnamaldehyde derivatives
EP0103503A2 (en) N-substituted amides, their salts, process for their preparation and pharmaceutical compositions containing them
JPS6115060B2 (en)
US3923859A (en) Substituted fulvene acetic acids and derivatives
JP3097281B2 (en) Synthesis of benzyl ether of phloroglucin-type phenol
JPS6115059B2 (en)
KR790001667B1 (en) Process for the preparation of bis-trimethoxy benzyl piperazyno alkanes
JPS598251B2 (en) Synthesis method of isoprenyl chalcone
KR820001124B1 (en) Process for preparing n-alkenyl moranoline derivatives
JPS627900B2 (en)
US4732909A (en) 3-(3-halophenyl-3,4-diazatetracyclo-[6.3.1.16,10.01,5 ]tridec-4-en-2-one compounds and use thereof to treat hypoxia
JPS5936607B2 (en) Method for producing long chain unsaturated alkyl ether